High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation

Journal of Virology

Volumn 70, Issue 7, 1996, Pages 4509-4516

  Xianqiang, L I ^a   Coffino, Philip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAPILLOMAVIRUS PROTEIN E 6; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; WART VIRUS;

EID: 8944239884     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.7.4509-4516.1996     Document Type: Article

References (55)

1. cdc2 kinase motif. Oncogene 5:423-426.
2. Banks, L., G. Matlashewski, and L. V. Crawford. 1986. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem. 159:529-534.
3. Bargonetti, J., J. J. Manfredi, X. Chen, D. R. Marshak, and C. Prives. 1993. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 7:2565-2574.
4. Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor-suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
5. Chowdary, D. R., J. J. Dermody, K. K. Jha, and H. L. Ozer. 1994. Accumulation of p53 in a mutant cell line defective in ubiquitin pathway. Mol. Cell. Biol. 14:1997-2003.
6. Crook, T., J. A. Tidy, and K. H. Vousden. 1991. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67:547-556.
7. Decaprio, J. A., J. W. Ludlow, J. Figge, J. Y. Shew, C. M. Huang, W. H. Lee, E. Marsillo, E. Paucha, and D. M. Livingston. 1988. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54:275-283.
8. Deveraux, Q., V. Ustrell, C. Pickart, and M. Rechsteiner. 1994. A 26 S protease subunit that binds ubiquitin conjugates. J. Biol. Chem. 269:7059-7061.
9. Diller, L., J. Kassel, C. E. Nelson, M. A. Gryka, G. Litwak, M. Gebhardt, B. Bressac, M. Ozturk, S. J. Baker, B. Vogelstein, and S. H. Friend. 1990. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol. 10:5772-5781.
10. Durst, M., R. T. Dzaelieva-Petrusevska, P. Boukamp, N. E. Fussenig, and L. Gissman. 1987. Molecular and cytogenetic analysis of immortalized human ketatinocytes obtained after transfection with human papillomavirus type 16 DNA. Oncogene 1:251-256.
11. El-Deiry, W. S., T. Tokino, V. E. Vewlculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
12. Fields, S., and K. K. Jang. 1990. Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046-1049.
13. Foster, S. A., G. W. Demers, E. G. Etscheid, and D. A. Galloway. 1994. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol. 68:5698-5705.
14. Gannon, J. V., R. Greaves, R. Iggo, and D. P. Lane. 1990. Activating mutations in p53 produce a common conformational effect, a monoclonal antibody specific for the mutant form. EMBO J. 9:1595-1602.
15. Gu, Y., C. W. Turck, and D. O. Morgan. 1993. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature (London) 366:707-710.
16. Harlow, E., L. V. Crawford, D. C. Pim, and N. M. Williamson. 1981 Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Virol. 39: 861-869.
17. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinascs. Cell 75:805-816.
18. Hawley-Nelson, P., K. H. Vousden, N. L. Hubert, and D. R. Lowy, and J. T. Schiller. 1989. HPV 16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 8:3905-3910.
19. Hershko, A., and A. Ciechanover. 1992. The ubiquitin system for protein degradation. Annu. Rev. Biochem. 61:761-807.
20. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253:49-53.
21. Huibregtse, J. M., M. Scheffner, and P. M. Howley. 1991. A cellular protein mediates association of p53 with the E6 oncoprotein of human papilloma-virus types 16 or 18. EMBO J. 10:4129-4135.
22. Huibregtse, J. M., M. Scheffner, and P. M. Howley. 1993. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus En oncoprotein with p53. Mol. Cell. Biol. 13:775-784.
23. Iwabuchi, K., B. Li, P. Bartel, and S. Fields. 1993. Use of the two-hybrid system to identify the domain of p53 involved in oligomerization. Oncogene 8:1693-1696.
24. Kao, C. C., P. R. Yew, and A. J. Berk. 1990. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology 179:806-814.
25. Kastan, M. B., Q. Zhan, W. S. EI-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 71:587-597.
26. Kaur, P., and J. K. McDougal. 1988. Characterization of primary human keratinocytes transformed by human papillomavirus type 18. J. Virol. 62: 1917-1924.
27. Lane, D. P., and L. V. Crawford. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature (London) 278:261-263.
28. Lechner, M, S., and L. A. Laimins. 1994. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J. Virol. 68:4262-4273.
29. Lechner, M. S., D. H. Mack, A. B. Finicle, T. Crook, K. H. Vousden, and L. A. Laimins. 1992. Human papillomavirus E6 protein bind p53 in vivo and abrogate p53-mediatcd repression of transcription. EMBO J. 8:3045-3052.
30. Levine, A. J., J. Momand, and C. A. Finlay. 1991. The p53 tumor suppressor gene. Nature (London) 351:453-456.
31. Li, X., and P. Coffino. 1993. Degradation of ornithinc decarboxylase: exposure of the C-terminal target by a polyamine-inducible inhibitory protein. Mol. Cell. Biol. 13:2377-2383.
32. Linzer, D. I. H., and A. J. Levine. 1979. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52.
33. Mansur, C. P., B. Marcus, S. Dalal, and E. J. Androphy. 1995. The domain of p53 requited for binding HPV 16 E6 is separable from the degradation domain. Oncogene 10:457-465.
34. Medcalf, E. A., and J. Milner. 1993. Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation. Oncogene 8:2847-2851.
35. Munger, K., W. C. Phelps, V. Bubb, P. M. Howley, and R. Schlegel. 1989. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keralinocytes. J. Virol. 63:4417-4421.
36. Munger, K., B. A. Werness, N. Dyson, W. C. Phelps, E. Hawlow, and P. M. Howley. 1989. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8:4099-4105.
37. Oren, M., W. Maltzman, and A. J. Levine. 1981. Posttranslational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol. Cell. Biol. 1:101-110.
38. Pavletich, N. P., K. A. Chambers, and C. O. Pabo. 1993. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Gene Dev. 7:2556-2564.
39. Pirisi, L., S. Yasumoto, S. M. Fellerey, J. K. Doniger, and J. A. DiPaolo. 1987. Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J. Virol. 61:1061-1066.
40. Raycroft, L., H. Wu, and G. Lozano. 1990. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogcne. Science 249:1049-1051.
41. Reich, N. C., M. Oren, and A. J. Levine. 1983. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol. Cell. Biol. 3:2143-2150.
42. Reihsaus, E., M. Kohler, S. Kraiss, M. Oren, and M. Montenarh. 1990. Regulation of the level of the ancoprotein p53 in non-transformed and transformed cells. Oncogene 5:137-145.
43. Ruppert, J. M., and B. Stillman. 1993. Analysis of a protein-binding domain of p53. Mol. Cell. Biol. 13:3811-3820.
44. Sarnow, P., Y. S. Ho, J. Williams, and A. J. Levine. 1982. Adenovirus Elb-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28:387-394.
45. Scheffner, M., J. M. Huibregtse, R. D. Vierstra, and P. M. Howley. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
46. Scheffner, M., T. Takahashi, J. M. Huibregtse, J. D. Minna, and P. M. Howley. 1992. Interaction of human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins. J. Virol. 66:5100-5105.
47. Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotcin encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
48. Shaulsky, G., N. Goldfinger, A. Ben-Ze'ev, and V. Rotter. 1990. Nuclear accumulation of p53 protein is mediated by several nuclear location signals and plays a role in tumorigenesis. Mol. Cell. Biol. 10:6565-6577.
49. Smith, D. B., and K. S. Johnson. 1988. Single-step purification of polypep- tides expressed in Eschcrichia coli as fusions with glutathione S-transferase. Gene 67:31-40.
50. Sturzbecher, H. W., R. Brain, C. Addison, K. Rudge, M. Remm, M. Grimaldi, E. Keenan, and J. R. Jenkins. 1992. A C-terminal α-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7:1513-1523.
51. Wade-Evans, A., and J. R. Jenkins. 1985. Precise epitope mapping of the murine transformation-associated protein, p53. EMBO J. 4:699-706.
52. Wang, Y., M. Reed, P. Wang, J. E. Stenger, G. Mayr, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1993. p53 domains: identification and charac- terization of two autonomous DNA-binding regions. Genes Dev. 7:2575-2565.
53. Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79.
54. Xiong, Y., G. J. Hannon, H. Shag, D. Cassia, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature (London) 366: 701-704.
55. Zakul-Houri, R., B. Bienz-Tadmor, D. Givol, and M. Oren. 1985. Human p53 cellular tumor antigen: cDNA sequence and expression. EMBO J. 4:1251-1255.